10 Best Weight Loss Drug Stocks to Buy According to Analysts

5. GSK plc (NYSE:GSK)

Price Target Upside: 28.28%

GSK plc (NYSE:GSK) develops and markets a wide range of healthcare products, including vaccines, specialty medicines, and general medicines. Its portfolio includes prescription drugs, over-the-counter medications, and vaccines targeting a variety of diseases and conditions.

GSK plc (NYSE:GSK) has been involved in the weight loss market with its over-the-counter product, alli (orlistat 60 mg), which was approved by the European Commission in 2009 as the first non-prescription weight loss aid in Europe. Alli works by preventing the absorption of some dietary fat in the digestive system, helping users lose 50% more weight when combined with a reduced-calorie diet. Despite initial success, Alli has faced challenges, including declining sales and a 2014 recall in the U.S. and Puerto Rico. The corporation continues to invest in weight management solutions and supports obesity-related research and consumer programs, positioning itself as one of the best weight loss drug stocks.

For fiscal Q4 2024, GSK plc (NYSE:GSK) released impressive financial results that showed a robust increase in all important parameters. In 2024, its core operating profit increased by 13% while its sales increased by 8% to nearly £31 billion. Core profits per share (EPS) increased by 12% as well.

GSK plc (NYSE:GSK)’s Specialty Medicines business saw a 19% increase in sales, which was credited with this success. Its oncology revenues almost doubled to over £1.4 billion in 2024, while its HIV sales increased by 13%. With five new product approvals expected in 2025 and 11 successful phase III studies reported in 2024, the company is steadily bolstering its pipeline. These include depemokimab for severe asthma and Blenrep for multiple myeloma.